Home
/
Treatment
/
N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxy}phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate

N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxy}phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate

	N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxy}phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate
Trade Name
Orphan Indication	Ovarian cancer
USA Market Approval	USA
USA Designation Date	2014-10-21 00:00:00
Sponsor	Amgen, Inc.;One Amgen Center Drive, Mail Stop 17-2-B;Thousand Oaks, California, 91320

Related Access Program

AstraZeneca – PSR Ovarian Cancer With a BRCA Mutation Tesaro, Inc. – Recurrent Ovarian Cancer AstraZeneca – Ovarian Cancer